Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$104.55 USD

104.55
1,628,734

-0.27 (-0.26%)

Updated May 23, 2024 12:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (144 out of 249)

Industry: Medical - Products

Better trading starts here.

Zacks News

Acadia Healthcare (ACHC) Tops Q4 Earnings, Gives 2017 View

Acadia Healthcare Company Inc. (ACHC) reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents.

    Parth Panchal headshot

    Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results

    Abbott Laboratories (ABT) just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.

      Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line

      Abbott Laboratories (ABT) reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate.

        Abbott Laboratories (ABT): Tops Q4 Earnings, Sales in Line

        Abbott Laboratories (ABT) earnings per share has beaten the Zacks Consensus Estimated while its revenues were almost in line with the mar.

          Tracey Ryniec headshot

          3 Stocks with Great Earnings Charts

          Looking for stocks that beat on earnings nearly every quarter?

            What's in Store for Abbott Labs (ABT) This Earnings Season?

            Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

              IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index

              IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.

                Abbott Labs to Close St. Jude Acquisition Later this Week

                Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.

                  AbbVie's Humira and Imbruvica Drive Performance in 2016

                  AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

                    Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout

                    Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).

                      Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs

                      Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.

                        Mark Vickery headshot

                        Q3 Earnings Continue, Housing and Permits Mixed

                        Housing starts fell 9% but building permits rose 6.3%. We also see earnings results from Morgan Stanley, U.S. Bancorp, Abbott Labs, Halliburton and Seagate.

                          Mark Vickery headshot

                          Q2 Earnings Season Coming Up Roses

                          Morgan Stanley, Abbott Labs and Halliburton all beat earnings expectations before the opening bell today.

                            Kevin Cook headshot

                            Bear of the Day: AbbVie (ABBV)

                            Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus

                              Sheraz Mian headshot

                              Parade of Mixed Earnings

                              Stocks have made solid gains in recent sessions, pushing the S&P 500 index above the 2100 level.

                                Eric Dutram headshot

                                Bear of the Day: Abbott Labs (ABT)

                                This stock could infect your portfolio thanks to its sluggish outlook and crumbling earnings estimates.